Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors

Sharifi N, Gulley JL, Dahut WL: Androgen deprivation therapy for prostate cancer. JAMA 2005, 294:238–244.

Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003, 95:981–989.

Barry MJ, Delorenzo MA, Walker-Corkery ES, et al.: The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int 2006, 98:973–978.

Shahinian VB, Kuo YF, Freeman JL, et al.: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103:1615–1624.

Keating NL, O’Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation for prostate cancer. J Clin Oncol 2006, 24:4448–4456.

Saigal CS, Gore JL, Krupski TL, et al.: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110:1493–1500.

Tsai HK, D’Amico AV, Sadetsky N, et al.: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516–1524.

D’Amico AV, Denham JW, Crook J, et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25:2420–2425.

Efstathiou JA, Bae K, Shipley WU, et al.: Cardiovascular mortality and duration of androgen deprivation therapy for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008 (in press).

Vermeulen A, Goemaere S, Kaufman JM: Testosterone, body composition and aging. J Endocrinol Invest 1999, 22:110–116.

Tayek JA, Heber D, Byerley LO, et al.: Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolism 1990, 39:1314–1319.

Smith JC, Bennett S, Evans LM, et al.: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86:4261–4267.

Smith MR, Finkelstein JS, McGovern FJ, et al.: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599–603.

Berruti A, Dogliotti L, Terrone C, et al.: Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002, 167:2361–2367; discussion 2367.

Smith M: Changes in fat and lean body mass during androgen deprivation therapy for prostate cancer. Urology 2004, 63:742–745.

Lee H, McGovern K, Finkelstein JS, Smith MR: Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104:1633–1637.

Page ST, Herbst KL, Amory JK, et al.: Testosterone administration suppresses adiponectin levels in men. J Androl 2005, 26:85–92.

Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008 (in press).

Smith MR, Lee H, McGovern FJ, et al.: Metabolic changes during gonadotropin releasing hormone (GnRH) agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008 (in press).

Hotta K, Funahashi T, Arita Y, et al.: Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595–1599.

Kumada M, Kihara S, Sumitsuji S, et al.: Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23:85–89.

Rothenbacher D, Brenner H, Marz W, Koenig W: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005, 26:1640–1646.

Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730–1737.

Lindsay RS, Resnick HE, Zhu J, et al.: Adiponectin and coronary heart disease: the Strong Heart Study. Arterioscler Thromb Vasc Biol 2005, 25:e15–e16.

Lawlor DA, Davey Smith G, Ebrahim S, et al.: Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677–5683.

Laughlin GA, Barrett-Connor E, May S, Langenberg C: Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study. Am J Epidemiol 2007, 165:164–174.

Eri LM, Urdal P, Bechensteen AG: Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100–104.

Smith MR, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305–1308.

American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31(Suppl 1):S55–S60.

Despres JP, Lamarche B, Mauriege P, et al.: Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996, 334:952–957.

Braga-Basaria M, Dobs AS, Muller DC, et al.: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24:3979–3983.

Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289–2304.

Ferrannini E: Metabolic syndrome: a solution in search of a problem. J Clin Endocrinol Metab 2007, 92:396–398.

Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393–403.

Smith MR: Selective estrogen receptor modulators to prevent treatment-related osteoporosis. Rev Urol 2005, 7(Suppl 3):S30–S35.

Erkkola R, Mattila L, Powles T, et al.: Bone mineral density and lipid changes during 5 years of follow-up in a study of prevention of breast cancer with toremifene in healthy, high-risk pre-and post-menopausal women. Breast Cancer Res Treat 2005, 93:277–287.

Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000, 63:225–234.

Saarto T, Blomqvist C, Ehnholm C, et al.: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996, 14:429–433.

Smith M, Malkowicz SB, Chu F, et al.: Toremifene improves lipid profiles in men receiving androgen deprivation therapy for prostate cancer-interim analysis of a multicenter phase III study. J Clin Oncol 2008 (in press).